Biotuesdays.com

Bio Tuesdays. Offers the latest news on the healthcare industry’s corporate and clinical developments, executive moves and market updates.

Today's Biotuesdays.com headlines: Observe fresh posts and updates on Bio Tuesdays. It is pretty active and updates frequently with 40+ articles published this month alone (they might potentially reach about 15.1K visitors within the said period of time). It is generally safe for browsing, so you may click any item to proceed to the site.

News, stories and media buzz related to Bio Tuesdays

Subscribe to related news

Ocular Therapeutix Reports Third Quarter 2016 Financial Results and Provides Corporate Update
via investingnews

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the third quarter ended September...
Titan Pharmaceuticals Announces FDA Approval of Probuphine(R) for the Treatment of Opioid Dependence
via saudieyeonbusiness

SOUTH SAN FRANCISCO, CA—(Marketwired – May 26, 2016) – Titan Pharmaceuticals, Inc. ( NASDAQ : TTNP ) today announced that the U.S. Food and Drug Administration has approved Probuphine® (buprenorphine) implant, the first product for the long–term maintenance...
Titan Pharmaceuticals Receives $15 Million Milestone Payment Following FDA Approval of Probuphine(R)
via marketportalegypt

SOUTH SAN FRANCISCO, CA—(Marketwired – Jun 13, 2016) – Titan Pharmaceuticals, Inc. ( NASDAQ : TTNP ) today announced it has received a $15 million milestone payment from development and commercialization partner Braeburn Pharmaceuticals following the...
Titan Pharmaceuticals Announces Presentation of Probuphine Phase 3 Data at American Society of Addiction Medicine Annual...
via sauditopbusiness

SOUTH SAN FRANCISCO, CA—(Marketwired – Apr 15, 2016) – Titan Pharmaceuticals, Inc. ( NASDAQ : TTNP ) announced today the presentation of data from the last Phase 3 study of Probuphine®, a six month subdermal buprenorphine implant for the long–term maintenance...
Titan Pharmaceuticals Reports Second Quarter 2016 Financial Results
via kuwaitfinancialexpress

SOUTH SAN FRANCISCO, CA—(Marketwired – Aug 9, 2016) – Titan Pharmaceuticals, Inc. ( NASDAQ : TTNP ), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long–term...

Biotuesdays.com popular pages

BioTuesdays | The Latest in Healthcare Industry News and Market Reports

BioTuesdays - offers the latest news on the healthcare industry’s corporate and clinical developments, executive moves and market updates.